InsidersTradesSigma
Follow the ブライトパス・バイオ株式会社 share price and the full directors' dealings record of the company, a listed issuer based in Japan. Shares trade on the JP market, under the supervision of EDINET (Japan FSA). Operating in the Health Care sector, ブライトパス・バイオ株式会社 has recorded 31 reports. Market capitalisation: €6.9bn. The latest transaction was reported on 11 July 2025 (Holding update). Among the most active insiders: Evo Fund. Every trade is accessible without an account.
31
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,791 of 29,068 companies
26.5
score / 100
Value11
Quality42
FCF yld-20%
Earn yld-19%
EV/EBITDA·
ROE-79%
Gross mgn64%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 July 2025
Declarations31 total
ShareXTKSEDINET:S100U3ZE
1.0% of flowShareXTKSEDINET:S100U13R
2.6% of flowShareXTKSEDINET:S100T74Z
43.1% of flowShareXTKSEDINET:S100T1HQ
9.3% of flowShareXTKSEDINET:S100T0GW
6.3% of flowShareXTKSEDINET:S100SY98
3.9% of flowShareXTKSEDINET:S100SVH4
8.3% of flowShareXTKSEDINET:S100SP3A
25 of 31 declarations
About ブライトパス・バイオ株式会社
BrightPath Biotherapeutics is a company focused on the health and pharmaceutical sector, dedicated to developing innovative therapies. It is listed on the XTKS market.